The global pandemic turned Moderna into a household name as one of the primary COVID-19 vaccine manufacturers. Now, according to a recent FiercePharma article, the company is investing $500 million in a manufacturing facility in Kenya. First announced in October of 2021, the site will focus on the production of up to 500 million vaccines a year. In the future, the site could expand to include fill-finish and packaging capabilities under the same roof. Though the exact location and size of the facility have yet to be disclosed, the company is planning to have the site built and operational by 2023.
Moderna to Open mRNA Manufacturing Facility in Kenya
The $500 million state-of-the-art site will produce up to 500 million vaccine doses a year.
Mar 11, 2022
Recommended
Recommended
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
